LabCompass

Andrew Johns

Medicine · The Ohio State University

Established · publishing since 1989

Publications

79

Citations

630

Est. group size

~10

Recurring co-author estimate

Active years

38

Publishing since 1989

Research summary
AI-generated

Andrew Johns is a clinical cancer researcher focused on genitourinary cancers, including kidney (renal cell carcinoma), testicular germ cell tumors, and penile cancer. His work centers on evaluating immunotherapy combinations and other drug treatments in clinical trials, as well as identifying biological markers that could help predict how patients respond to treatment. Prospective students would likely engage with multi-institutional clinical trial data, patient outcome analyses, and translational research connecting tumor biology to treatment strategies.

Kidney cancer (renal cell carcinoma) immunotherapyTesticular germ cell tumor biologyPenile squamous cell carcinoma biomarkersImmune checkpoint blockade combination therapiesClinical trial outcomes in genitourinary cancers

Publication output has grown substantially over the last decade, rising from just a few papers per year in 2017-2018 to a peak of 17 in 2025, indicating an increasingly active research program.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026

Publication cadence
Publications per year over the last 10 years — averaging 7.8/year recently
2017: 2 publications172018: 1 publication182019: 5 publications192020: 9 publications202021: 12 publications212022: 3 publications222023: 5 publications232024: 7 publications242025: 17 publications17252026: 7 publications26
Recent publications
Publishes in
  • Journal of Clinical Oncology×23
  • Cancer Immunology Immunotherapy×5
  • The Oncologist×4
  • Journal of Thoracic Oncology×4
  • Clinical Lung Cancer×2
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 19, 2026.

Claim or correct this profile